Kazia Therapeutics Appoints James Levine as Chief Financial Officer
KZIA has more than doubled off its 52-week low of $3.544.
Summary
Kazia Therapeutics appointed James Levine, an experienced biotech and investment banking executive, as its new Chief Financial Officer, including a substantial equity grant.
Key Events · Executive and Board Changes · KZIA
-
New Chief Financial Officer Appointed
James Levine, with over two decades of experience in investment banking and biotech financial leadership, has been appointed CFO, effective June 1, 2026.
-
Significant Equity Compensation
Mr. Levine will receive options over 200,000 American Depositary Shares (ADSs), valued at approximately $2.57 million based on the current stock price, with a vesting schedule.
-
Strategic Leadership Role
The CFO will lead finance, capital markets, investor relations, and corporate finance strategy, playing a key role in the company's ongoing clinical and corporate development.
Analysis · KZIA · Life Sciences
This filing updates the company's prospectus by incorporating a concurrent 6-K announcing the appointment of James Levine as Chief Financial Officer. Mr. Levine brings extensive experience from investment banking and executive roles in biotech. His compensation package includes a significant equity grant of 200,000 ADSs options, aligning his interests with shareholders. This appointment fills a critical leadership role as the company advances its clinical pipeline.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $12.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $142.4M. The 52-week trading range was $3.54 to $17.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.